AbsintaMVuoloLRaoA, et al. Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis. Neurology2015; 85(1): 18–28.
2.
ZivadinovRRamasamyDPVaneckovaM, et al. Leptomeningeal contrast enhancement is associated with progression of cortical atrophy in MS: A retrospective, pilot, observational longitudinal study. Mult Scler2017; 23(10): 1336–1345.
3.
HarrisonDMWangKYFiolJ, et al. Leptomeningeal enhancement at 7T in multiple sclerosis: Frequency, morphology, and relationship to cortical volume. J Neuroimaging2017; 27(5): 461–468.
4.
MakshakovGMagonovETotolyanN, et al. Leptomeningeal contrast enhancement is associated with disability progression and grey matter atrophy in multiple sclerosis. Neurol Res Int2017; 2017: 8652463.
5.
BergslandNRamasamyDTavazziE, et al. Leptomeningeal contrast enhancement is related to focal cortical thinning in relapsing-remitting multiple sclerosis: A cross-sectional MRI study. AJNR Am J Neuroradiol2019; 40(4): 620–625.
6.
AbsintaMCorteseICVuoloL, et al. Leptomeningeal gadolinium enhancement across the spectrum of chronic neuroinflammatory diseases. Neurology2017; 88(15): 1439–1444.
7.
IghaniMJonasSIzbudakI, et al. No association between cortical lesions and leptomeningeal enhancement on 7-Tesla MRI in multiple sclerosis. Mult Scler2020; 26(2): 165–176.
8.
ZurawskiJTauhidSChuR, et al. 7T MRI cerebral leptomeningeal enhancement is common in relapsing-remitting multiple sclerosis and is associated with cortical and thalamic lesions. Mult Scler2020; 26(2): 177–187.
9.
PittDBosterAPeiW, et al. Imaging cortical lesions in multiple sclerosis with ultra-high-field magnetic resonance imaging. Arch Neurol2010; 67(7): 812–818.
10.
JonkmanLEKlaverRFleysherL, et al. Ultra-high-field MRI visualization of cortical multiple sclerosis lesions with T2 and T2*: A postmortem MRI and histopathology study. AJNR Am J Neuroradiol2015; 36(11): 2062–2067.
